Amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig's disease, is a progressive neurodegenerative disorder characterized by the selective loss of upper and lower motor neurons in the brain and spinal cord[1]. The disease leads to gradual muscle weakness, paralysis, and typically results in death within 2-5 years of symptom onset due to respiratory failure[2]. ALS represents the most common adult-onset motor neuron disease, with an incidence of approximately 1-2 per 100,000 persons annually and a prevalence of 4-8 per 100,000[3].
The clinical presentation of ALS is heterogeneous, with patients typically presenting with focal weakness that progresses in a regional pattern before becoming generalized[4]. Common initial symptoms include limb weakness (60-70% of cases), bulbar involvement (25-30%), and respiratory insufficiency (5-10%)[5]. The disease follows an ascending pattern of progression, with contiguous body regions becoming affected over time[6].
ALS exhibits a uniform worldwide incidence of approximately 1-2 cases per 100,000 population per year, with notable geographic variations[7]. The mean age of onset is 55-65 years for sporadic ALS and approximately 10 years earlier for familial cases[8]. Population-based studies indicate a slight male predominance (1.2-1.5:1 ratio), which is most pronounced in patients under 70 years of age[9].
The prevalence of ALS ranges from 4-8 per 100,000, with this figure relatively stable across populations despite the uniformly fatal outcome[10]. This relatively constant prevalence reflects the short survival duration, with median survival from symptom onset being 2-4 years and only 10-20% of patients surviving beyond 5 years[11].
Epidemiological studies have identified several risk factors for ALS, though the etiology remains incompletely understood in the majority of cases. Approximately 5-10% of ALS cases are familial, following autosomal dominant inheritance with incomplete penetrance[12]. The remaining 90-95% are classified as sporadic, with no clear family history.
Environmental factors implicated in ALS pathogenesis include smoking, which increases risk by approximately 1.5-2-fold[13]. Physical activity has shown inconsistent associations, with some studies suggesting increased risk in elite athletes and others showing protective effects of moderate exercise[14]. Other potential risk factors include exposure to heavy metals, pesticides, and head trauma, though evidence remains inconsistent[15].
Approximately 5-10% of ALS cases are hereditary, with over 25 genes implicated in familial ALS[16]. The major causative genes include:
C9orf72 — The most common genetic cause of ALS worldwide, accounting for approximately 40% of familial ALS and 5-10% of sporadic ALS[17]. Hexanucleotide repeat expansions in the first intron of C9orf72 represent the most frequent mutation, with >30 repeats considered pathogenic. The normal allele contains <30 repeats, while affected individuals may have hundreds to thousands of repeats[18]. This mutation also causes frontotemporal dementia (FTD), explaining the clinical overlap between these disorders.
SOD1 — Mutations in the copper/zinc superoxide dismutase gene account for approximately 12-20% of familial ALS[19]. Over 150 pathogenic SOD1 variants have been identified, with the A4V mutation being the most common in North America and associated with rapid disease progression[20]. SOD1 mutations cause disease through toxic gain-of-function mechanisms rather than loss of enzymatic activity.
FUS — Mutations in the fused in sarcoma gene account for approximately 5% of familial ALS[21]. Most mutations are clustered in the nuclear localization sequence and lead to cytoplasmic mislocalization of FUS protein. FUS mutations are associated with earlier disease onset (median 39 years) and more rapid progression compared to other genetic forms[22].
TARDBP — Mutations in the TAR DNA-binding protein gene (TARDBP) account for approximately 3-5% of familial ALS[23]. Like FUS, TARDBP mutations cause cytoplasmic accumulation of TDP-43 protein, which is the major component of inclusion bodies in most ALS cases[24].
Genome-wide association studies (GWAS) have identified multiple risk loci for sporadic ALS, though effect sizes are modest[25]. The strongest associations include:
ALS is characterized by the selective degeneration of both upper motor neurons (corticospinal tract neurons) and lower motor neurons (anterior horn cells and bulbar motor nuclei)[29]. The pattern of involvement is focal initially, spreading contiguously to adjacent regions over time[30]. This propagation may occur through prion-like templating of protein aggregates or through neural network connections[31].
The pathological hallmarks of ALS include:
Multiple interconnected pathogenic mechanisms contribute to motor neuron degeneration in ALS:
RNA Metabolism Dysregulation — Mutations in RNA-binding proteins (TDP-43, FUS) disrupt normal RNA processing, including splicing, transport, and translation[36]. These defects lead to abnormal protein aggregation and loss of function for critical neuronal proteins[37].
Oxidative Stress — Motor neurons are particularly vulnerable to oxidative damage due to high metabolic demands and relatively low antioxidant capacity[38]. SOD1 mutations directly increase oxidative stress, and evidence of oxidative damage to proteins, lipids, and DNA is found in both familial and sporadic ALS[39].
Excitotoxicity — Excessive glutamate signaling through AMPA and NMDA receptors can lead to calcium influx and excitotoxic cell death[40]. The finding that riluzole (an anti-glutamatergic drug) provides modest survival benefit supports this mechanism[41].
Mitochondrial Dysfunction — Abnormal mitochondria with reduced function are consistently observed in ALS motor neurons[42]. This defect leads to energy failure, increased reactive oxygen species production, and activation of apoptotic pathways[43].
Impaired Proteostasis — Both TDP-43 and SOD1 aggregates indicate failure of protein quality control systems[44]. Autophagy and ubiquitin-proteasome system dysfunction allows toxic protein accumulation[45].
Neuroinflammation — Activated microglia and astrocytes surround motor neurons in ALS, producing pro-inflammatory cytokines that may contribute to disease progression[46].
ALS typically presents with insidious onset of focal weakness, with the pattern reflecting the region of initial motor neuron involvement[47]. The most common presentations include:
Limb-onset ALS (70%) — Weakness beginning in one limb, typically presenting as foot drop, hand weakness, or proximal arm weakness. Fasciculations and muscle atrophy often accompany the weakness[48].
Bulbar-onset ALS (25-30%) — Difficulty with speech (dysarthria) and swallowing (dysphagia) as initial symptoms. Tongue fasciculations and weakness are characteristically present[49].
Respiratory-onset ALS (5-10%) — Presents with dyspnea, orthopnea, or nocturnal hypoventilation. This presentation carries the poorest prognosis[50].
Following onset, ALS progresses in a predictable pattern with involvement of adjacent body regions. Progression typically follows a contiguity model, with adjacent spinal segments affected in sequence[51]. However, the pattern and rate of progression vary considerably between individuals.
The progression leads to:
The El Escorial revised criteria and Awaji criteria provide standardized diagnostic classification for ALS[53][54]:
Definite ALS — Presence of upper and lower motor neuron signs in three body regions (bulbar, cervical, thoracic, lumbosacral)
Probable ALS — Upper and lower motor neuron signs in at least two regions, with some signs in one region extending to another
Possible ALS — Upper and lower motor neuron signs in one region, or upper motor neuron signs in two regions, or lower motor neuron signs in two regions
Suspected ALS — Lower motor neuron predominance in two or more regions
Diagnosis of ALS is primarily clinical, based on history, neurological examination, and electrophysiological studies[55]. The diagnostic process involves:
History — Progressive muscle weakness, typically starting in one body region and spreading contiguously. Presence of fasciculations, cramps, and difficulty with fine motor tasks[56].
Neurological Examination — Evidence of both upper motor neuron signs (hyperreflexia, spasticity, pathological reflexes) and lower motor neuron signs (weakness, atrophy, fasciculations)[57].
Electrophysiology — Needle electromyography shows widespread denervation and reinnervation consistent with motor neuron disease. Nerve conduction studies are typically normal, helping to exclude peripheral neuropathies[58].
While no definitive test for ALS exists, several investigations support the diagnosis and rule out mimics:
MRI Brain and Spine — Rule out structural lesions, compression, or alternative pathologies. May show corticospinal tract hyperintensity or signal changes in ALS[59].
Genetic Testing — Increasingly important for diagnosis, prognostication, and family counseling. Testing for C9orf72, SOD1, FUS, and TARDBP is available[60].
Laboratory Tests — Routine blood work to exclude metabolic, inflammatory, and infectious mimics. Anti-GM1 antibodies may be present in motor neuropathy variants[61].
Riluzole — The first FDA-approved disease-modifying therapy for ALS, approved in 1995. Riluzole inhibits glutamate release and reduces glutamatergic neurotransmission[62]. Clinical trials demonstrate modest survival benefit (2-3 months) with minimal functional improvement[63].
Edaravone — Approved by FDA in 2017 based on randomized controlled trial showing slower functional decline in patients receiving intravenous edaravone[64]. The mechanism involves reduction of oxidative stress, though the exact therapeutic effect remains incompletely understood[65].
AMX0035 (sodium phenylbutyrate/taurursodiol) — Approved in 2022 based on the CENTAUR trial showing significant survival benefit (median 4.8 months) and slower functional decline[66].
Relyvrio (AMX0035) — FDA approved combination therapy that targets mitochondrial dysfunction and energy failure in ALS[67].
Comprehensive multidisciplinary care is essential for optimal outcomes in ALS:
Respiratory Care — Non-invasive ventilation (BiPAP) improves survival and quality of life in patients with respiratory dysfunction[68]. Bulbar dysfunction may require volume ventilation. Timely discussion of tracheostomy and long-term ventilation is important[69].
Nutritional Support — Malnutrition worsens outcomes in ALS. Percutaneous endoscopic gastrostomy (PEG) placement provides reliable nutrition when oral intake becomes unsafe or insufficient[70].
Spasticity Management — Baclofen, tizanidine, and benzodiazepines provide symptomatic relief for spasticity. Botulinum toxin injections may help focal spasticity[71].
Communication Aids — Augmentative and alternative communication devices become essential as speech fails. Eye-tracking and brain-computer interfaces provide communication options[72].
Multiple therapeutic strategies are under investigation:
Gene Therapy — Antisense oligonucleotides targeting SOD1 (tofersen) have shown promise in clinical trials, with recent positive results supporting accelerated approval[73]. Gene therapy approaches for C9orf72 and other genetic forms are in development[74].
Cell-Based Therapies — Clinical trials of stem cell transplantation have explored neuroprotective and immunomodulatory approaches, though definitive benefits remain elusive[75].
Small Molecule Drugs — Numerous compounds targeting various pathogenic mechanisms are in clinical trials, including mitochondrial protectors, anti-excitotoxic agents, and anti-inflammatory compounds[76].
Reliable biomarkers for diagnosis, prognosis, and therapeutic monitoring remain an urgent need in ALS. Promising biomarker candidates include:
Neurofilament Light Chain (NfL) — Elevated in cerebrospinal fluid and blood, correlates with disease progression and survival[77]. NfL shows promise for monitoring treatment response in clinical trials[78].
Genetic Biomarkers — C9orf72 repeat size, SOD1 mutation type, and other genetic factors influence prognosis and may predict treatment response[79].
Recent advances in trial methodology include:
Platform Trials — Master protocols allowing multiple simultaneous treatments within a single trial structure, improving efficiency[80].
Enrichment Strategies — Selecting patients based on genetic subtypes or biomarkers may improve signal detection[81].
Outcome Measures — Development of more sensitive clinical endpoints and patient-reported outcomes[82].
Amyotrophic lateral sclerosis represents a devastating neurodegenerative disease with profound impacts on patients, families, and healthcare systems. While our understanding of ALS pathogenesis has advanced considerably—from the identification of major genetic causes to elucidation of molecular mechanisms—no curative treatment exists. The development of disease-modifying therapies including riluzole, edaravone, and AMX0035 provides hope, while emerging gene therapies and immunomodulatory approaches offer promise for the future. Comprehensive multidisciplinary care remains essential for optimizing quality of life and survival in ALS patients.
Brown RH, Al-Chalabi A. Amyotrophic Lateral Sclerosis. N Engl J Med. 2017. ↩︎
Chio A, Logroscino G, Hardiman O, et al. Prognostic factors in ALS: A critical review. Amyotroph Lateral Scler. 2009. ↩︎
Marin B, Boumediene F, Logroscino G, et al. Variation in worldwide incidence of amyotrophic lateral sclerosis: a meta-analysis. Int J Epidemiol. 2017. ↩︎
Kiernan MC, Vucic S, Cheah BC, et al. [Amyotrophic lateral sclerosis](https://doi.org/10.1016/S0140-6736(10). Lancet. 2011. ↩︎
Chio A, Traynor BJ. [The genetics of amyotrophic lateral sclerosis](https://doi.org/10.1016/S1474-4422(15). Lancet Neurol. 2015. ↩︎
Ravits J, Laurie P, Fu QG, et al. Implications of ALS focality and contiguity on mechanisms of disease spread. Neurology. 2007. ↩︎
Al-Chalabi A, Hardiman O, Kiernan MC, et al. Amyotrophic lateral sclerosis: moving towards a new classification system. Lancet Neurol. 2016. ↩︎
Chiò A, Traynor BJ, Lombardo F, et al. Prevalence of SOD1 mutations in the Italian ALS population. Neurology. 2008. ↩︎
Manjaly ZR, Scott KM, Abhinav K, et al. The sex ratio in amyotrophic lateral sclerosis: a population based study. Amyotroph Lateral Scler. 2010. ↩︎
Logroscino G, Marin B, Piccininni M, et al. Global, regional, and national burden of ALS: a systematic analysis for the Global Burden of Disease Study 2017. Lancet Neurol. 2017. ↩︎
Kimura Y, Ando K, Kondo K, et al. Survival and prognostic factors in sporadic ALS: systematic review and meta-analysis. J Neurol Neurosurg Psychiatry. 2023. ↩︎
Mathis S, Goizet C, Soulages A, et al. Genetics of amyotrophic lateral sclerosis: A review. J Neurol Sci. 2019. ↩︎
Wang MD, Little J, Gomes J, et al. Identification of modifiable and non-modifiable risk factors in ALS: a systematic review. Amyotroph Lateral Scler Frontotemporal Degener. 2017. ↩︎
Lacorte E, Ferraro L, Klaric E, et al. Physical activity and amyotrophic lateral sclerosis: a systematic review. Neurol Sci. 2020. ↩︎
Bozzoni V, Pansarasa O, Diamanti L, et al. Amyotrophic lateral sclerosis and environmental factors. Funct Neurol. 2016. ↩︎
Brennan M, McCarthy R, Ryan E, et al. Identifying genetic variants in amyotrophic lateral sclerosis: a systematic review of genome-wide association studies. J Neurol Sci. 2023. ↩︎
Renton AE, Majounie E, Waite A, et al. A hexanucleotide repeat expansion in C9ORF72 is the cause of chromosome 9p21-linked ALS-FTD. Neuron. 2011. ↩︎
DeJesus-Hernandez M, Mackenzie IR, Boeve BF, et al. Expanded GGGGCC hexanucleotide repeat in noncoding region of C9ORF72 causes chromosome 9p-linked FTD and ALS. Neuron. 2011. ↩︎
Rosen DR, Siddique T, Patterson D, et al. Mutations in Cu/Zn superoxide dismutase gene are associated with familial amyotrophic lateral sclerosis. Nature. 1993. ↩︎
Cudkowicz M, McKenna-Yasek D, Sapp PE, et al. Epidemiology of SOD1 mutations in amyotrophic lateral sclerosis. Neurology. 1999. ↩︎
Kwiatkowski TJ, Bosco DA, Leclerc AL, et al. Mutations in the FUS/TLS gene on chromosome 16 cause familial amyotrophic lateral sclerosis. Science. 2009. ↩︎
Conte A, Lattante S, Marangi G, et al. FUS mutations in amyotrophic lateral sclerosis: clinical features, neurophysiology and therapeutic implications. Amyotroph Lateral Scler. 2012. ↩︎
Sreedharan J, Blair IP, Tripathi VB, et al. TDP-43 mutations in familial and sporadic amyotrophic lateral sclerosis. Science. 2008. ↩︎
Neumann M, Sampathu DM, Kwong LK, et al. Ubiquitinated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Science. 2006. ↩︎
Nicolas A, Kenna KP, Renton AE, et al. Genome-wide analyses identify novel variants associated with ALS susceptibility and progression. Nat Neurosci. 2018. ↩︎
Diekstra FP, van Vught PW, van Rheenen W, et al. UNC13A is a modifier of survival in amyotrophic lateral sclerosis. Neurology. 2012. ↩︎
Soraru G, Trevisan L, Gellera C, et al. CAG repeat size in ATXN2 influences clinical features in ALS. Neurology. 2013. ↩︎
van Vught PW, Sutedja NA, Veldink JH, et al. Novel genetic risk variants for amyotrophic lateral sclerosis. Lancet Neurol. 2023. ↩︎
Hardiman O, Al-Chalabi A, Chio A, et al. Amyotrophic lateral sclerosis. Nat Rev Dis Primers. 2017. ↩︎
Ravits JM, La Spada AR. ALS motor phenotype heterogeneity, focality, and spread: deconstructing motor neuron degeneration. Neurology. 2009. ↩︎
Polymenidou M, Cleveland DW. Prion-like spread of protein aggregates in neurodegeneration. J Clin Invest. 2012. ↩︎
Charcot JM. Amyotrophic lateral sclerosis. Arch Neurol. 1969. ↩︎
Bunina T. [On intracellular inclusions in motor neurons in amyotrophic lateral sclerosis]. Zh Nevropatol Psikhiatr Im S S Korsakova. 1962. ↩︎
Arai T, Hasegawa M, Akiyama H, et al. TDP-43 is a component of ubiquitin-positive tau-negative inclusions in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Biochem Biophys Res Commun. 2006. ↩︎
Dickson DW. Neuropathology of amyotrophic lateral sclerosis. Neurol Clin. 2007. ↩︎
Ling SC, Polymenidou M, Cleveland DW. Converging mechanisms in ALS and FTD: disrupted RNA and protein homeostasis. Neuron. 2013. ↩︎
Lagier-Tourenne C, Cleveland DW. Rethinking ALS: FUS comes into focus. Neuron. 2009. ↩︎
Barber SC, Shaw PJ. Oxidative stress in ALS: key role in motor neuron injury and therapeutic potential. Free Radic Biol Med. 2010. ↩︎
Andrus PK, Flemming JR, Price CJ, et al. Protein oxidative damage in a transgenic mouse model of familial amyotrophic lateral sclerosis. J Neurol Sci. 1998. ↩︎
Van Damme P, Bogaert E, Dewil M, et al. Restoring glutamate homeostasis in ALS: a new therapeutic target. Lancet Neurol. 2009. ↩︎
Bensimon G, Lacomblez L, Meininger V. A controlled trial of riluzole in amyotrophic lateral sclerosis. N Engl J Med. 1994. ↩︎
Mórotz GM, De Vos KJ, Vagnoni A, et al. Mitochondrial dysfunction in amyotrophic lateral sclerosis. J Neurochem. 2022. ↩︎
Pizzuto J, Genovese N, Bartley S, et al. Mitochondrial dynamics and quality control in ALS. Neurology. 2019. ↩︎
Chen S, Zhang X, Song L, et al. Autophagy dysfunction in ALS. Neurol Res. 2022. ↩︎
Wong YC, Holzbaur ELF. The regulation of autophagosome dynamics by huntingtin and HAP40. EMBO J. 2014. ↩︎
Huang K, Chen C, Liu Y, et al. Neuroinflammation in amyotrophic lateral sclerosis. Brain Res Bull. 2022. ↩︎
Chio A, Gamba C, Pagano M, et al. Frequency and pattern of clinical presentation in Italian ALS patients. Neurol Sci. 2014. ↩︎
Eisen A, Weber N. The motor cortex and amyotrophic lateral sclerosis. Eur Neurol. 2001. ↩︎
Körner S, Finsel F, Wittstock M, et al. Dysphagia in amyotrophic lateral sclerosis: the ALS Clinical Staging System. J Neurol Sci. 2011. ↩︎
Chio A. Respiratory onset of ALS: a challenge for patients and caregivers. Amyotroph Lateral Scler. 2010. ↩︎
Ravits J. Focality, spread, and contiguity in amyotrophic lateral sclerosis. Adv Exp Med Biol. 2021. ↩︎
Phukan J, Pender NP, Hardiman O. Cognitive impairment in amyotrophic lateral sclerosis. Lancet Neurol. 2007. ↩︎
World Federation of Neurology Research Group on Motor Neuron Diseases. El Escorial revisited: revised criteria for the diagnosis of amyotrophic lateral sclerosis. Amyotroph Lateral Scler Other Motor Neuron Disord. 2000. ↩︎
Costa J, Swash M, de Carvalho M. Awaji criteria for the diagnosis of ALS: what do we really know? J Neurol Neurosurg Psychiatry. J Neurol Neurosurg Psychiatry. 2012. ↩︎
EFNS Task Force on Diagnosis and Management of Amyotrophic Lateral Sclerosis. EFNS guidelines on the Clinical Management of Amyotrophic Lateral Sclerosis (MALS). Eur J Neurol. 2012. ↩︎
Benatar M, Wozniak E. Recognizing and evaluating amyotrophic lateral sclerosis. Med Clin North Am. 2019. ↩︎
Swinnen B, Robberecht W. The phenotypic variability of amyotrophic lateral sclerosis. Nat Rev Neurol. 2014. ↩︎
de Carvalho M, Dengler R, Eisen A, et al. Electrodiagnostic criteria for diagnosis of ALS: clinical consensus. Amyotroph Lateral Scler. 2008. ↩︎
Chang JL, Lomen-Hoerth C, Murphy J, et al. A voxel-based morphometry study of patterns of brain atrophy in ALS and ALS with dementia. Neurology. 2005. ↩︎
Chio A, Traynor BJ, Battistini S, et al. Genetic testing in amyotrophic lateral sclerosis: a critical review. Neurology. 2012. ↩︎
Liguori R, Difford J. ALS mimics: the differential diagnosis. Handb Clin Neurol. 2022. ↩︎
Dambach H, Huttner HB, Bähr M. Riluzole in ALS: current status and future prospects. Nat Rev Neurol. 2022. ↩︎
Miller RG, Mitchell JD, Moore DH. Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND). Cochrane Database Syst Rev. 2012. ↩︎
Writing Group, Edaravone (MCI-186) ALS Study Group. Safety and efficacy of edaravone in well-defined patients with amyotrophic lateral sclerosis: a randomised, double-blind, placebo-controlled trial. Lancet Neurol. 2017. ↩︎
Yoshino H, Kimura A. Investigation of the therapeutic mechanism of edaravone in ALS. J Neurol Sci. 2021. ↩︎
Paganoni S, Macklin EA, Gottlieb A, et al. Long-term survival of participants in the CENTAUR trial of AMX0035 in ALS. Neurology. 2023. ↩︎
FDA. FDA Approves New Treatment Option for ALS. 2022. 2022. ↩︎
Bourke SC, Tomlinson M, Williams TL, et al. Effects of non-invasive ventilation on survival and quality of life in patients with amyotrophic lateral sclerosis: a randomised controlled trial. Lancet Neurol. 2006. ↩︎
Hardiman O, van den Berg LH, Kiernan MC. Clinical diagnosis and management of amyotrophic lateral sclerosis. Nat Rev Neurol. 2011. ↩︎
Naito Y, Haraoka H, Hamada S, et al. Role of nutritional intervention in amyotrophic lateral sclerosis: a systematic review. J Neurol Sci. 2023. ↩︎
Dal Bello-Haas V, Kloos AD, Mitsumoto H. Physical management of amyotrophic lateral sclerosis. Neurol Clin. 1998. ↩︎
Beukelman D, Fager S, Nordness A. Communication support for people with ALS. Nat Rev Neurol. 2011. ↩︎
Miller TM, Cudkowicz ME, Shaw PJ, et al. Antisense oligonucleotides targeting SOD1 in familial ALS: a phase 1, randomized, first-in-human trial. Lancet Neurol. 2023. ↩︎
Liu Y, Dodart JC, Ralph MS. Gene therapy for ALS: progress and future perspectives. Mol Ther. 2023. ↩︎
Goutman SA, Savelieff MG, Jang J, et al. Stem cell therapies for amyotrophic lateral sclerosis: recent advances and future perspectives. J Neurol Sci. 2023. ↩︎
Jaiswal MK. Riluzole and edaravone: a tale of two drugs. Curr Med Chem. 2019. ↩︎
Benatar M, Waning L. Neurofilament light chain as a biomarker in ALS. Lancet Neurol. 2021. ↩︎
Lu CH, Petzold A, Topp J, et al. Neurofilament light chain as a disease biomarker in a prospective ALS cohort. Neurology. 2019. ↩︎
Chio A, Pagano M. Genetic testing in ALS: clinical implications and future directions. Lancet Neurol. 2015. ↩︎
Ivanova L, Zetterberg J, Portelius E, et al. Platform trials in ALS: new approaches to accelerate therapeutic development. Ann Neurol. 2023. ↩︎
van den Berg LH. Toward biomarker-driven trials in ALS. Neurology. 2019. ↩︎
Benatar M, Berry J, Hynan L. Defining clinically meaningful endpoints in ALS. Amyotroph Lateral Scler. 2023. ↩︎